Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Afinitor
(United States) [Available] ,Afinitor Disperz
(United States) [Available] ,Torpenz
(United States) [Available]Synonyms :
Everolimus
Class :
Antineoplastics and miscellaneous drugs
10
mg
Orally
once a day
the total duration of therapy is continued until disease progression or no toxicity occurs
Note:
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
4.5
mg/m^2
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
4.5
mg/m^2
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
when everolimus is used in combination with diphtheria & tetanus toxoids, this leads to a reduction in the effects of diphtheria & tetanus toxoids through pharmacodynamic antagonism
nafcillin will decrease the effect of action of everolimus by affecting enzyme CYP3A4 metabolism.
interaction raises immunosuppressive effects and risk of infection
everolimus increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of everolimus
may inhibit P-glycoprotein (MDR1) efflux transporter by reducing the concentrations and activities
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may enhance the concentration of serum when combined with everolimus
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
everolimus: they may enhance the serum concentration of glycoprotein Inhibitors
When encainide is used together with everolimus, this leads to a reduction in the encainide’s metabolism
When everolimus is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
When everolimus is used in combination with rabies vaccine, this leads to a reduction in the rabies vaccine effects through the process of pharmacodynamic antagonism
poliovirus vaccine inactivatedÂ
everolimus reduces the effects of the poliovirus vaccine when pharmacodynamic antagonists are present
When everolimus is used together with ridaforolimus, this leads to enhanced concentration serum of everolimus
the effect of everolimus is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
fedratinib increases the effect of everolimus by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
It may enhance the risk of adverse reactions when combined with Enzymes
When everolimus is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
Actions and spectrum:Â
Afinitor:Â
Zortress:Â
It inhibits the proliferation and activation of B and T lymphocytes stimulated by antigens and interleukin (IL-2 and IL-15); binds to the cellular cytoplasmic protein, FK506 Binding Protein-12 (FKBP-12), forming an immunosuppressive complex that is everolimus- FKBP-12 which binds and inhibits the mTOR (mammalian Target Of Rapamycin), a critical regulatory kinase.Â
Frequency definedÂ
>10%Â
Anorexia
Asthenia
Anemia
Fatigue
Cough
Diarrhea
Headache
Epistaxis
Pneumonitis
Menstrual irregularities
Nausea
Stomatitis
Constipation
Infections
Edema
Dyspnea
Pyrexia
Vomiting
Rash
1-10%Â Â
Congestive heart failureÂ
Dysgeusia
HemorrhageÂ
Tachycardia
Black Box Warning Â
No specific black box warnings are available Â
Contraindication/Caution: nn                                                       Â
Contraindication:Â
HypersensitivityÂ
Caution:Â
Non-infectious pneumonitisÂ
Pneumocystis jiroveci pneumoniaÂ
Stomatitis Â
Renal failureÂ
Angioedema  Â
ContraindicationsÂ
(Zostress only)Â
Kidney graft thrombosisÂ
Heart transplantationÂ
CautionÂ
Nephrotoxicity Â
Â
Pregnancy Warnings:Â
Pregnancy category:
AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned
Lactation:Â
Excretion of the drug into human breast milk is unknownÂ
Pregnancy Categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â
Everolimus is a kinase inhibitor and a selective immunosuppressant used to treat organ transplant rejection and certain cancerous and noncancerous tumors. Â
Pharmacodynamics:Â
Data not available Â
Pharmacokinetics:Â
AbsorptionÂ
Peak plasma time may be attained in 1 to 2 hours. The high-fat diet reduces the peak plasma concentration.
DistributionÂ
74% of everolimus is known to be bound to proteins. The volume of distribution in kidney transplant patients is observed to be 107 to 342 L.Â
MetabolismÂ
Everolimus undergoes hepatic metabolism. It is a CYP3A4 and pgP substrate.
Elimination and excretionÂ
80% of the drug is known to be eliminated through feces, while 5% through urine.Â
Half-life:Â
30hours Â
Administration:Â
Administer suspension or tablets orally at the same time each dayÂ
Â
Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
